Reference: GILA/ID/MA-065/CLIN
Board seat: Independent Director, Non-Executive
Primary board location: Hyderabad with Indian and Southeast Asian operations
Meeting model: Six boards, quarterly Quality/Audit and integration reviews
Mandate type: Merger, Demerger & Post-Acquisition Board Build
Status: Confidential live-search specification; client identity released only after conflict clearance and NDA.
The anonymised enterprise
A listed life-sciences services company has acquired a Southeast Asian clinical-data-management and pharmacovigilance business serving global sponsors.
The acquisition adds 2,000+ employees and materially increases access to patient and safety data across jurisdictions. Seller systems and quality processes will run in parallel for at least one year.
The board problem and strategic reason for appointment
Integration speed cannot compromise case processing, audit trails, privacy or sponsor commitments. The independent director must ensure that cost synergy does not reduce quality-unit independence or create undisclosed processing risk.
The board is not buying a credential. It is appointing an independent decision-maker who can convert this problem into a governed sequence of choices, evidence and accountability. Success will be judged by the quality of decisions and control improvement, not by the number of recommendations made.
Board position, authority and interfaces
Chair of Quality/Technology Risk and Audit member; interfaces with acquired subsidiary board and DPOs.
The appointee will have direct, unfiltered access to the Company Secretary and to the relevant control-function leaders. Any advisory support requested by the board must remain management-executed: the director sets questions, tolerances and evidence standards, but does not become an executive or consultant.
First 12–18 month strategic charter
- Set quality and data migration gates before system consolidation; map sponsor consents, data localisation and cross-border processing; review case backlog, timeliness, reconciliation and audit-trail integrity; govern workforce synergy, key-person retention and seller TSA exit without quality degradation
- Define the board’s transaction-to-integration bridge: synergy evidence, stranded cost, customer and talent retention, control migration, Day-1 authority and the conditions that trigger reconsideration of the deal thesis.
- Protect minority and entity-level interests where group, seller, buyer and joint-venture priorities diverge; ensure related-party and transfer-pricing decisions have independent challenge.
Decision profile sought
Essential evidence
- Clinical data, pharmacovigilance, quality, privacy or cross-border services executive; integration board experience; regulated data judgement
Differentiators
- Health-data migration, sponsor audit or serious quality-backlog recovery; Southeast Asian operations
GILA will assess integration or separation experience, entity-level fiduciary judgement, transaction accounting literacy and the ability to detect when reported synergy masks transferred risk. Candidates should expect a case discussion based on an ambiguous board decision from this mandate, not a career-history interview alone.
Independence, suitability and downside diligence
The search will apply Section 149(6), Sections 164–165, Schedule IV and the applicable listing or sector rules to the entity’s legally verified status at the appointment date. Databank/proficiency status, listed-entity directorship and committee ceilings, pecuniary relationships, relatives’ interests, recent audit/advisory work and interlocking directorships will be checked. The appointment is subject to formal legal and secretarial confirmation; this posting is not a substitute for that determination.
Mandate-specific screens: Sponsor, seller, technology vendor, CRO competitor or quality-consultant interests; involvement in pre-deal diligence that creates self-review.
Before accepting the seat, the candidate will receive under NDA the latest board composition, committee charters, material litigation/regulatory schedule, related-party map, last audited accounts, current D&O policy and the specific risk papers necessary to make an informed liability assessment.
Twelve-month outcomes
The board expects a newly combined, separated or jointly controlled business with functioning governance, transparent economics and no orphaned critical risks. For this particular seat, the evidence will be:
- No missed safety-reporting obligations; migrations pass quality/privacy gates; TSA and workforce integration close without sponsor or control loss
Commitment, protection and economics
- Expected load: 24–30 days annually in integration.
- Terms: Five-year term; chair differential; cyber, professional, regulatory and D&O cover.
- Protection: Appointment letter, deed of indemnity where legally available, appropriate D&O cover including discovery/run-off terms, access to independent advice under the board-approved protocol, and complete minuting of dissent.
- Equity: No stock options where the appointment is legally an independent-director seat subject to Section 149(9). Any private-company structure outside that perimeter will be expressly classified and separately advised; no equity is implied by this posting.
Search process
Conflict pre-clearance → GILA/SYMPHONY™ board-fit interview → mandate case → document-led diligence under NDA → references from board peers and control functions → NRC/owner interviews → statutory, regulatory and reputation checks → board recommendation. Candidate consent, disclosures and appointment approvals will follow the law and the entity’s constitutional documents.